“CLINICAL-PATOGENETIC RATIONALE FOR THE USE OF GLYCOSAMINOGLYCANS IN THE TREATMENT OF PATIENTS WITH GLOMERULONEPHRITIS”, Scientific and practical journal, vol. 28, no. 4, pp. 88–93, Dec. 2023, doi: 10.21802/artm.2023.4.28.88.